FDA-approved Drug Cracks Cancer’s Invisible Wall

Colorful pills and a rainbow ribbon on a pink background

A rare liver cancer that strikes mostly young adults has found a way to lock the immune system out — and a Cornell University team just found the key that may open the door.

Story Snapshot

Fibrolamellar carcinoma traps T cells at the edge of tumors, blocking them from killing cancer cells — researchers now know why.
An existing Food and Drug Administration (FDA)-approved drug called AMD3100 breaks that trap and frees T cells to enter the tumor core.
When combined with immune checkpoint therapy, AMD3100 caused a significant increase in tumor cell death in patient tissue tests.
No human clinical trials have started yet — but the drug’s existing FDA approval may speed that process considerably.

A Rare Cancer That Hides From Your Own Immune System

Fibrolamellar carcinoma is a rare liver cancer with no standard treatment. It mostly strikes teenagers and young adults with no history of liver disease. That alone makes it cruel. What makes it worse is that the body’s own immune system shows up to fight — and then gets stopped cold at the tumor’s edge. Immunotherapy, which works by unleashing the immune system on cancer, has shown only a 15.8% response rate in fibrolamellar patients. ^[4] That number tells you everything about how hard this cancer is to crack.

The immune system’s front-line fighters are called T cells. In most cancers where immunotherapy works, T cells push into the tumor and destroy it from the inside. In fibrolamellar carcinoma, something different happens. The tumor creates what researchers describe as an immune “no entry” zone. T cells pile up at the outer edge but never get in. They are not absent — they are trapped. Understanding that distinction is what made the Cornell University breakthrough possible.

How AMD3100 Forces Open the Tumor’s Locked Door

Cornell researchers found that fibrolamellar tumors actively pull T cells away from the tumor core and hold them at the edges — a process called sequestration. AMD3100 blocks that process. The drug prevents the tumor from corralling T cells, freeing them to move into the core where they can do damage. Testing on actual patient tumor slices, conducted by a team at the University of Washington, confirmed that AMD3100 effectively mobilized T cells into the tumor interior. ^[1] That is a meaningful result, not a computer model or an animal study.

The combination of AMD3100 with immune checkpoint inhibitors — drugs that remove the “off switch” cancer uses to shut down T cells — produced a significant increase in tumor cell death during those patient slice tests. ^[1] Checkpoint inhibitors alone were not enough. AMD3100 alone was not enough. Together, they created a one-two punch that the tumor could not deflect. That synergy is exactly what researchers have been hunting for in this disease for years.

The FDA-Approval Advantage That Could Save Years

AMD3100, also known as Plerixafor, is already FDA-approved for a different condition involving bone marrow stem cell mobilization. That matters enormously. Developing a brand-new cancer drug from scratch takes an average of more than a decade. Repurposing an already-approved drug cuts that timeline significantly — research shows the average gap between a drug’s first approval and its repurposing for a new use is about 7.2 years, far shorter than starting from zero. ^[13] The FDA is actively encouraging this kind of repurposing for rare diseases right now, calling for ideas from researchers and patients alike.

What the Science Cannot Yet Tell Us

The honest read on this research requires holding two things at once. The mechanism is compelling and the early results are real. But no human being has been treated with this combination yet. The Cornell team is currently searching for liver cancer clinicians willing to start clinical trials. ^[1] There is no survival data, no long-term response data, and no safety data for this specific drug combination in fibrolamellar patients. The tumor slice results are promising — but a slice of tumor in a lab dish is not a living patient with a complex immune system and other health variables.

Fibrolamellar carcinoma is also extraordinarily rare, which creates a practical problem. The largest study ever done on immunotherapy in this cancer involved only 19 patients. ^[4] Running a statistically powerful clinical trial with those enrollment numbers is genuinely hard. Recruiting enough patients to produce clean data takes time, coordination across multiple medical centers, and sustained funding — none of which is guaranteed for a rare cancer that lacks a large pharmaceutical market. These are not reasons to dismiss the research. They are reasons to watch it carefully and push for trials to begin.

Why This Research Deserves Serious Attention Right Now

Drug repurposing has already changed cancer treatment in ways most people do not realize. Thalidomide, once infamous for birth defects, became a cornerstone treatment for multiple myeloma. Metformin, a cheap diabetes drug, is now being tested across multiple cancers. The pattern is real and well-documented. AMD3100 fits squarely into that tradition — a known drug, a newly understood mechanism, and a patient population with no good options. The science published February 17, 2026, in the journal Gastroenterology gives clinicians a clear and testable hypothesis. That is how breakthroughs begin.